

## REDUCED PAIN MEDICATION AFTER 2<sup>ND</sup> LUMBAR SURGERY

### Provant<sup>®</sup> Therapy resulted in improved physical activity, reduced pain score, and reduced pain medication usage

April 2016 Newsletter

**CASE REPORT:** 50 year old male with degenerative disc disease underwent a L4-L5 lumbar fusion. In the immediate post-operative period the patient suffered a fracture when attempting to transfer from the operating table, resulting in severe axial pain in his L-S spine and numbness in the right leg and foot. High doses of gabapentin (3600 mg/day), Cymbalta, and oxycodone were prescribed with minimal symptom relief. After four months a second surgery was performed to remove bone fragments, a screw, and a rod. Baseline pain score at discharge was 5-6/10. Pain medications were gabapentin 600 mg/day combined with oxycodone. Provant Therapy was started three days post-op. After 11 weeks of Provant, pain was 0-1/10 at rest and 2-3/10 with activity. Gabapentin was reduced to 300 mg/day and oxycodone was discontinued. The patient became more active and began physical therapy. Strength and range of motion improved.

	Before Provant	After Provant
<b>Pain Meds</b>	<ul style="list-style-type: none"> <li>• <b>Pre-op:</b> Gabapentin 3600 mg/day; hydrocodone/acetaminophen</li> <li>• <b>At discharge:</b> Gabapentin 600 mg/day; oxycodone.</li> </ul>	<ul style="list-style-type: none"> <li>• Gabapentin 300 mg/day</li> <li>• Off the oxycodone</li> </ul>
<b>Pain Score</b> 0-10	5-6/10	0-1/10 2-3/10 with activity
<b>Quality of Life</b>	<ul style="list-style-type: none"> <li>• Not able to stand for long periods of time</li> <li>• Minimal strength and endurance</li> </ul>	<ul style="list-style-type: none"> <li>• Increased strength and endurance</li> <li>• Able to stand longer</li> <li>• Improved range of motion</li> </ul>

This safe, non-drug pain management therapy has provided relief for over 12,000 patients. To learn more how Provant may help your patients, please contact your RegenesiS representative, or visit [www.regenesiSbio.com](http://www.regenesiSbio.com).

If you have colleagues that would like to receive these monthly newsletters, please forward this email to them; they may subscribe by emailing us at [newsletter@regenesiSbio.com](mailto:newsletter@regenesiSbio.com).

Sincerely,



Adrienne (Patti) Smith, MD  
 Vice President, Clinical Business and Medical Affairs  
[patti.smith@regenesiSbio.com](mailto:patti.smith@regenesiSbio.com)